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Abstract. Although recent developments in imaging biomarkers have revolutionized the diagnosis of Alzheimer’s disease at
early stages, the utility of most of these techniques in clinical setting remains unclear. The aim of this review is to provide
a clear stepwise algorithm on using multitier imaging biomarkers for the diagnosis of Alzheimer’s disease to be used by
clinicians and radiologists for day-to-day practice. We summarized the role of most common imaging techniques and their
appropriate clinical use based on current consensus guidelines and recommendations with brief sections on acquisition and
analysis techniques for each imaging modality. Structural imaging, preferably MRI or alternatively high resolution CT, is the
essential first tier of imaging. It improves the accuracy of clinical diagnosis and excludes other potential pathologies. When
the results of clinical examination and structural imaging, assessed by dementia expert, are still inconclusive, functional
imaging can be used as a more advanced option. PET with ligands such as amyloid tracers and 18F-fluorodeoxyglucose
can improve the sensitivity and specificity of diagnosis particularly at the early stages of the disease. There are, however,
limitations in using these techniques in wider community due to a combination of lack of facilities and expertise to interpret
the findings. The role of some of the more recent imaging techniques including tau imaging, functional MRI, or diffusion
tensor imaging in clinical practice, remains to be established in the ongoing and future studies.
Keywords: Alzheimer’s disease, biomarkers, guidelines, imaging, magnetic resonance imaging, positron emission
tomography
INTRODUCTION
Despite all the advances in imaging of Alzheimer’s
disease (AD) in the research setting, there is a lack
of translation of these methodologies into the clini-
cal practice. Most imaging biomarkers have not been
validated in unselected patient cohorts and partici-
pants in large AD studies are not representative of the
general population. These techniques require special
facilities and expertise to perform and interpret. The
paucity of standard acquisition and analysis methods
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between different centers make the widespread adop-
tion of them even more challenging. In addition, some
of the new imaging modalities are still too expensive
to be considered cost-effective in a community setting
or in non-specialized centers.
Based on a growing body of evidence, the early
and accurate diagnosis in preclinical stages of the
disease is paramount to tackle AD [1, 2]. Therefore,
an important goal of developing imaging biomarkers
should be to bridge the gap between the research set-
ting and clinical practice and to use these techniques
as screening, diagnostic, or prognostic markers in the
wider population.
In this review, we summarize the utility of
different imaging biomarkers, review the current
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guidelines and recommendations, and present a
stepwise algorithm for radiological evaluation of cog-
nitive impairment for clinicians. We will also review
some of the novel techniques, which may not come
to clinical practice in the near future, to demonstrate
their potential utility.
STRUCTURAL IMAGING
Current recommendation and guidelines
There is a consensus among all current guide-
lines that structural imaging, i.e., magnetic resonance
imaging (MRI) or computerized tomography (CT),
is required for evaluation of patients presenting with
a cognitive/dementia syndrome (CDS) in the clinical
setting [3–7]. The UK National Institute of Health and
Care Excellence [3], European Federation of Neu-
rological Societies (EFNS) [4, 8], and the Fourth
Canadian Consensus Conference on Diagnosis and
Treatment of Dementia [6] have all recommended
using structural imaging to 1) exclude treatable
causes of dementia and 2) assess the pattern of atro-
phy which could provide additional diagnostic or
predictive values to clinical information. The pres-
ence of atrophy can improve the accuracy of a clinical
diagnosis considerably. Scheltens et al. showed the
incremental diagnostic gain of positive or negative
MRI for any given clinical probability [5]. MRI is
the preferable method because of its higher resolution
and ability to delineate a spectrum of changes related
to vascular pathologies and white matter diseases in
the brain. High resolution CT can be used as a replace-
ment when there is a contraindication for MRI. It has
also been recommended to use a standard MRI pro-
tocols for dementia to facilitate the comparison with
follow up imaging.
The characteristic pattern of atrophy in AD
involves structures of the medial temporal lobe
(MTL) including the hippocampi, entorhinal cortex,
parahippocampal gyrus, amygdala, and also the cin-
gulate cortex while the motor cortex is relatively
spared [9–11]. Despite all the evidence supporting the
presence of AD “signature” atrophy in large research
studies based on group level analysis, it is still very
challenging to quantify the degree of atrophy in a
single case in clinical setting.
Acquisition and analysis techniques
The minimum sequences required to assess a
patient with CDS are:
1) High resolution 3D/Volumetric T1 weighted
images produced with fast spoiled gradi-
ent echo (FSPGR; GE Healthcare), mag-
netization prepared rapid acquisition GRE
(MPRAGE; Siemens Healthineers) or other
similar sequences in coronal and at least one
more plane (axial or sagittal) which can be
produced using reformatting software. This
sequence is used to assess the anatomy, internal
structure and degree of atrophy;
2) T2 weighted images;
3) Fluid-attenuated inversion recovery (FLAIR)
sequence.
Both the latter are used to determine the severity of
vascular changes. In addition, a coronal FLAIR is the
best projection to evaluate the signal of hippocampi
and MTL.
Other sequences such as 4) Gradient echo
(GRE)/T2∗ /Susceptibility Weighted Imaging (SWI)
and 5) Diffusion weighted imaging can provide addi-
tional valuable information. SWI can detect cerebral
microbleeds, reflecting evidence of vascular amy-
loid pathology, which has both diagnostic role [12]
and therapeutic implication in anti amyloid treatment
[13]. Diffusion weighted images can exclude other
pathologies such as recent vascular events and more
importantly support the diagnosis of Creutzfeldt-
Jakob disease as a cause of subacute cognitive
impairment.
The following is a summary of different ways to
assess the hippocampal and MTL atrophy:
1) Visual assessment: scoring atrophy from 0 to 4
based on the width of the choroid fissure, max-
imum width of the temporal horn, and height
of hippocampal formation [14] (Fig. 1). This
is a technique widely used in a clinical set-
ting as it is not time consuming, does not
require either specialist software, calculations
or reformatting. The limitation of this method is
the significant inter-observer variation in scal-
ing atrophy [15–17]. Despite scoring variation
there is, however, good inter-rater reliability
when visual assessment is used to dichotomize
the data into presence or absence of atrophy
[15], which might be sufficient for clinical pur-
poses.
2) Linear (1D): Different methods are used for the
linear assessment of atrophy including measur-
ing the radial width of the temporal horn [18],
measurement of interuncal distance, [19] and
a grading scale (0–4) for the degree of medial
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Fig. 1. Visual assessment of MTL and hippocampal atrophy. a) largest vertical width of choroid fissure; b) width of temporal horn; c)
maximum vertical height of hippocampal formation. ↑, increase; ↓, decrease; N, normal.
temporal lobe atrophy using the area of the hip-
pocampi and maximal transverse width of the
temporal horns [20].
3) Planimetric (2D) measurements: These tech-
niques comprise assessment of the degree
of medial temporal lobe atrophy (MTA) by
measuring the whole MTL region including
the parenchyma and cerebrospinal fluid (CSF)
spaces (A), the parenchyma in the MTL region
(B) and the body of the ipsilateral lateral ven-
tricle (C) in the coronal images at the level of
interpeduncular fossa. Various parameters such
as 2D-MTA = A-B or Medial Temporal Atro-
phy index (MTAi) = (A-B) × 10/C have been
developed using these measurements [21–23].
Although all of the above techniques (linear and
planimetric) are feasible and can be assessed
on MRI images obtained in any clinical set-
ting, there is a lack of normative values to
distinguish normal from abnormal particularly
at early stage of disease such as minimal cog-
nitive impairment (MCI). Also, they have not
been used on large cohorts of patients and, in
comparison to volumetric measurements, they
are less accurate [24].
4) Volumetric measurement (3D): There are man-
ual and automated techniques for measuring the
volume of hippocampi. The manual segmenta-
tion by an expert is considered as gold standard
for hippocampal volumetry but it requires a
high level of training, is very time consum-
ing and costly. The other issue preventing it
from being used in the clinical setting is sig-
nificant variation in segmenting hippocampus
[25]. To overcome the discrepancies in the
segmentation of hippocampus between differ-
ent centers, the European Alzheimer’s Disease
Consortium (EADC) and Alzheimer’s Disease
Neuroimaging Initiative (ADNI) with support
of the Alzheimer’s Association have devel-
oped a consensual harmonisation protocol for
manual segmentation of hippocampus [26,
27] which is available as a web-based pro-
tocol (http://www.hippocampal-protocol.net).
The automated segmentation techniques can
overcome some of the reliability issues of man-
ual techniques, but extra software and expertise
is required to operate them efficiently. In addi-
tion, there is limited data on their sensitivity
and specificity and further validation is required
before they can be used in clinical practice
[25, 28].
In a multicenter European study, the accuracy of
different structural MRI techniques to distinguish AD
from healthy controls were compared. They found
accuracy of visual rating (81%), manual hippocam-
pal measurement (89%), and automated multivariate
analysis of hippocampal and MTL atrophy (83%)
were not significantly different [29].
Clinical implementation
The role of structural MRI differs based on the
clinical presentation, stage of the disease, and possi-
bility of an alternative diagnosis/mixed pathologies.
Figure 2 demonstrates a stepwise approach in assess-
ment of CDS in the clinic using structural MRI. If
a patient presented with a clinical picture compat-
ible with probable AD based on National Institute
of Aging- Alzheimer’s Association guideline (NIA-
AA) [30], with clinical probability of 0.5 and above
and MRI showed atrophy in AD signature regions, the
diagnosis is confirmed with a probability of between
0.9–1 [5]. For such a case in clinical setting and
assuming the patient will not be recruited to any
research study or new therapeutic clinical trial, no
further imaging will be required. Structural MRI can
also help to determine the severity of vascular disease
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Fig. 2. Summary of structural MRI applications in assessment of AD based on current guidelines and literature review.
and exclude other structural pathologies. However, if
the clinical picture is atypical because of the course of
the disease or presenting symptoms (non-amnestic),
then the initial role of MRI is mainly to exclude other
causes of cognitive impairment mimicking dementia
some of which can be treated if diagnosed promptly.
Examples of such conditions include limbic and
paraneoplastic encephalitides, different infections,
systemic and CNS inflammatory conditions, tumors,
and stroke. Atypical presentations warrant a more
thorough clinical assessment and detailed neuropsy-
chological examination to diagnose other types of
dementia and MRI can be useful in differentiat-
ing the pattern of atrophy in some of these cases
(Fig. 3). Once non-degenerative causes are excluded,
an atypical presentation should prompt consideration
of non-amnestic variants of AD: posterior corti-
cal atrophy presents with prominent visuospatial
impairment while the logopenic variant of primary
progressive aphasia (PPA) is characterized with
impairment of single word retrieval and repetition of
sentences. Moreover, the behavioral variant of AD
presents with a dysexecutive syndrome and impaired
behavior. Non-AD dementia syndromes should
always be a consideration in these atypical cases.
Frontotemporal dementias (FTD) can present with
abnormal behavior or impaired language. Evidence
of Parkinsonism should lead to consideration of other
diagnoses such as dementia with Lewy body (DLB)/
Parkinson’s disease dementia (PDD), if accompa-
nied by other clinical signs, namely supranuclear
gaze palsy and prominent asymmetrical apraxia, pro-
gressive supranuclear palsy (PSP) and corticobasal
degeneration (CBD) should be considered respec-
tively. MRI can be helpful in identifying the pattern
of atrophy associated with many less common forms
of dementia as detailed in Fig. 3. One important
caveat is that the absence of such atrophy patterns
does not exclude the condition as in many instances,
clinical syndromes might present without the “typi-
cal” atrophy pattern. In some diseases such as DLB/
PDD or CBD, no distinctive pattern of atrophy has
been identified. Mixed pathologies are also extremely
common especially with advancing age and the com-
bination of different pathologies can contaminate the
atrophy patterns of individual diseases. MRI is also
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Fig. 3. MRI images of common types of dementia in axial, coronal, and sagittal planes, a) early AD with hippocampal and MTL atrophy;
b) PCA with superior posterior parietal lobes atrophy; c) logopenic variant of PPA with atrophy in left temporoparietal junction; note more
prominent left sided atrophy of posterior and lateral temporal lobes; d) semantic variant of PPA with atrophy in anterior and lateral temporal
lobes; e) non-fluent variant of PPA with left frontal operculum and insular atrophy.
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insensitive when CDS is at its early stages (e.g., MCI)
and in these circumstances, it is advisable to move to
the next tier of imaging depending on availability and
clinical suspicion.
FUNCTIONAL IMAGING
Functional imaging includes positron emission
tomography (PET) with different tracers, single pho-
ton emission computed tomography (SPECT), and
advanced MRI techniques such as functional MRI
(fMRI), diffusion tensor imaging (DTI), MR spec-
troscopy (MRS) and arterial spin labeling (ASL).
Most of these imaging techniques have recently been
developed and some are still far from being used in the
routine clinical setting. For the purpose of this review,
we focused mainly on the well-established meth-
ods such as 18F-fluorodeoxyglucose (18F-FDG) PET,
SPECT, and amyloid PET. To make the algorithms
more practical, we adapted the new classification
scheme for AD biomarkers (A/T/N) introduced by
Jack et al. [31]. The utility and role of functional
imaging is hugely dependent on the clinical scenario
and availability of facilities and expertise but as a
general rule they can be used when the combination
of clinical examination and structural imaging fail to
determine the diagnosis.
FDG-PET
Cerebral hypometabolism is one of the main fea-
tures of AD. PET with 18F-FDG—a glucose analogue
that provides information on the first stages of the glu-
cose metabolism pathway, and a proxy for neuronal
and synaptic activity—is a well-established imaging
tool for the evaluation of brain function in dementia
disorders, including AD.
Current recommendations and guidelines
The European Federation of the Neurological Soci-
eties [4, 8], The UK National Institute of Health and
Care Excellence [3] and Fourth Canadian Consensus
Conference on Diagnosis and Treatment of Demen-
tia [6] all recommended using 18F-FDG-PET in cases
with dementia when despite clinical examination and
structural imaging by a dementia specialist the diag-
nosis still remains in doubt, preventing adequate
clinical management. There is partial consensus on
using FDG in MCI cases. In these cases FDG is use-
ful when the confirmation of a diagnosis can change
a patient’s clinical management [6]. FDG-PET can
also be used as a prognostic biomarker. AD pattern
hypometabolism in FDG-PET in a patient with MCI
can predict the conversion to AD within several years
[8]. In the US, using FDG-PET for differentiating AD
from other dementias (mostly FTD) is approved by
Medicare and Medicaid services.
In typical AD, 18F-FDG PET has consistently
demonstrated metabolic deficits in the medial tem-
poral lobe, parieto-temporal regions, precuneus,
posterior cingulate gyrus, and/or frontal cortices,
with sparing of the basal ganglia, thalamus, cerebel-
lum, and visual and sensorimotor cortices [32–35]
(Fig. 4). The extent of these hypometabolic patterns
during disease progression has been found to cor-
relate with patient performance on cognitive tests
[36], and the severity of dementia [35]. In addi-
tion, cerebral hypometabolism depicted by 18F-FDG
PET has also been shown to correlate with clini-
cal symptoms of cognitive impairment [37] and CSF
markers of AD pathology, such as A42 and phos-
phorylated tau-protein levels [38, 39]. In longitudinal
studies, 18F-FDG PET results have shown predictive
value in identifying healthy individuals progressing
to MCI, and MCI subjects converting to AD [35,
40–42]. Overall sensitivity of FDG is around 76%
and median specificity is 82% [43]. Additionally,
18F-FDG-PET can provide differential diagnosis of
dementias, allowing discrimination of AD from FTD
with more than 85% sensitivity and specificity [35,
44], and AD from DLB with >90% sensitivity and
70% specificity [45, 46].
Acquisition and analysis techniques
Dynamic 18F-FDG PET imaging with arterial
blood sampling can provide regional estimates of
cerebral glucose metabolic rate (CMRglc) as the most
accurate technique for assessing 18F-FDG uptake.
Arterial blood sampling, however, is a cumbersome
procedure for routine clinical use, due to its inva-
sive nature, associated discomfort and potential risk
to the patient. For diagnostic purposes and in clin-
ical settings, PET images can be assessed by visual
inspection. This, however, is greatly dependent on the
reader’s experience. The lack of clear cut-off between
normal and abnormal values can make it more chal-
lenging particularly in cases with mild disease. Thus,
clinical 18F-FDG dementia imaging usually utilizes
standardized uptake value ratio (SUVr) quantifica-
tion of static imaging typically performed as a 30 min
acquisition after an uptake period ranging from 30
to 60 min. During the uptake period, patients are
placed in a quiet, dimly-lit room to avoid enhanced
cerebral 18F-FDG uptake from neuronal activation.
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Fig. 4. MRI (top), FDG-PET (middle), and PiB-PET (bottom)
images of a typical AD case in axial (a), coronal (b) and sagit-
tal (c) planes showing hypometabolism in parietal and temporal
lobes in FDG-PET and extensive cortical amyloid deposition in
PiB-PET.
Furthermore, patients are required to fast for at least
4 h prior to tracer administration to minimize plasma
glucose-related inhibition of 18F-FDG delivery to tis-
sue. SUVr is determined relative to a region whose
metabolism is unaffected or mildly affected in AD;
these regions include the cerebellar cortex, vermis or
whole cerebellum, pons, putamen, visual and motor
cortices, or a composite of these [47, 48]. SUVr
approaches have shown robust results in assessing
metabolic deficits in AD, demonstrating good cor-
relations with clinical symptoms, cognitive scores
and dementia progression. Recently and in order
to facilitate the 18F-FDG-based assessment of AD,
two cut points have been defined to dichotomize
18F-FDG-PET data into normal and abnormal cat-
egories. The lenient cut point defined by an SUVr of
1.56 is based on the specificity, sensitivity and accu-
racy of 18F-FDG distinguishing cognitively impaired
cases from young healthy controls. The conserva-
tive cut point of an SUVr of 1.42 is based on
cognitively impaired versus age-matched healthy
controls [49]. It is should be noted however that
classification of an individual above a particular cut
value, using either lenient or conservative criteria,
does not necessarily preclude the absence of brain
pathology.
Clinical implementation
Hypometabolism in 18F-FDG-PET is a biomarker
of neurodegeneration, neuronal dysfunction and
synaptic disease, which is a relatively late finding
in the course of AD [50]. Hence normal 18F-FDG
in a case with a suspicious diagnosis of demen-
tia, although makes neurodegeneration very unlikely
[8], it cannot exclude early CDS. The result of
18F-FDG-PET in MCI/Preclinical AD can be sig-
nificantly variable from AD pattern abnormality to
cortical hypermetabolism [51, 52]. The pattern of
abnormality can also be different according to the
clinical presentation (amnestic or non amnestic) or
underlying pathology [53]. The utility of 18F-FDG-
PET in diagnosis of CDS is summarized in Fig. 5.
Although there are distinctive patterns of glucose
hypometabolism in different dementia syndromes,
i.e., AD, FTD, and DLB, these findings are based
on group differences and not at the individual level.
Interpretation of a single case can be more difficult
as there are overlaps between areas of abnormality
across these conditions. As a general rule, involve-
ment of temporoparietal lobes, symmetric or more
on the right [54] and posterior cingulate gyrus par-
ticularly is more in favor of AD. Anterior cerebral
involvement in frontal, anterior temporal lobes and
anterior cingulate gyrus is more common in FTD [44,
54], while posterior involvement in occipital lobes
particularly primary visual cortex is more seen in
DLB [46].
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Amyloid-PET (11C-Pittsburgh Compound B and
18F-Labelled Amyloid Tracers)
11C-Pittsburgh Compound B (11C-PiB), a deriva-
tive of the amyloid-binding histological dye,
thioflavin-T, is the best characterized PET tracer for
imaging cerebral amyloid- (A) deposition [55, 56].
11C-PiB has been shown to bind selectively with high
affinity to fibrillar A aggregates, but not amorphous
A deposits or neurofibrillary tangles [57, 58].
PET studies have demonstrated increased cortical
binding in brain areas known to be affected by fibril-
lar A pathology, notably frontal, temporo-parietal,
and posterior cingulate cortices [58, 59] (Fig. 4). Con-
versely, brain areas with low A plaque density, such
as the cerebellum, have minimal 11C-PiB binding.
In vivo patterns of 11C-PiB binding to A fibrils
agree with the regional distribution of A plaques
observed by postmortem immunohistochemistry [60,
61] and autopsy [62, 63]. Imaging with 11C-PiB has
been reported to differentiate between AD patients
and cognitively intact age-matched controls [59, 64],
predict progression of MCI to symptomatic AD [65,
66], as well as allow differential diagnosis of demen-
tias [67, 68]. 11C-PiB retention has also been shown
to be concordant with levels of CSF A42, underlin-
ing the potential of amyloid PET imaging as a marker
of prodromal AD [69]. Compared to 18F-FDG alone,
amyloid imaging has demonstrated greater accuracy
in the differentiation of patients with AD from healthy
controls [70].
Despite the proven efficacy of 11C-PiB in imag-
ing A-related neuropathology, the short half-life
of the 11C label (20 min) has restricted its use to
centers with an on-site cyclotron, hampering its use
for both research and clinical practice. To overcome
the impracticalities of 11C-PiB, several 18F-labelled
amyloid derivatives have emerged. Of these, the
18F-labelled PiB analogue, 18F-flutemetamol [71]
(GE-067; VizamylTM, GE Healthcare), the stilbene
derivative 18F-florbetapir [72] (AV-45; AMYViDTM,
Eli Lilly), and the strylpyridine derivative 18F-
florbetaben [73] (BAY-94-9172; NeuraceqTM, Pira-
mal) have all gained approval from the US Food and
Drug Administration (FDA) and European Medicines
Agency (EMA) for use as diagnostic agents of cere-
bral amyloid aggregation.
Similar to 11C-PiB, all three compounds have
exhibited high specific binding to fibrillar A plaques
in vivo, and strong correlations with autopsy and post-
mortem pathological findings [74–79]. Although
non-specific retention in white matter is higher for
these 18F-labelled tracers than for 11C-PiB, to date
this has not presented a major impediment in the
qualitative interpretation of images [71–73, 80–82].
Current recommendations and guidelines
The European Federation of the Neurological
Societies [8], the Amyloid Imaging Task Force
(Society for Nuclear Medicine and Molecular Imag-
ing and the Alzheimer’s Association) [83, 84], and
the recent Canadian Consensus Conference on the
Use of Amyloid Imaging [85] have similar recom-
mendations for clinical utilities of amyloid PET.
Similar to 18F-FDG-PET, there is a general con-
sensus that amyloid PET imaging should only be
used in dementia expert centers. Amyloid PET is
recommended for cases with objectively confirmed
cognitive impairment for whom, despite comprehen-
sive clinical/neuropsychological examinations and
structural imaging, the diagnosis remains uncertain.
Examples include 1) patients with a core clinical
diagnosis of possible AD with an atypical course
or presentation, early onset of symptoms (age < 65)
or cases who present with mixed or heterogeneous
syndromes; and 2) patients with persistent or pro-
gressive unexplained MCI in whom the knowledge
of amyloid status could provide precise diagnosis
or alter the management [8, 83–85]. It is inappro-
priate to use amyloid PET in cognitively normal
individuals, based solely on positive family history,
genetic testing, APOE4 status, or for nonmedical use
[83]. The European Federation of the Neurological
Societies also suggested that amyloid PET can be
used for differentiating FTD from AD and cerebral
amyloid angiopathy from other types of intracra-
nial hemorrhages [8]. Importantly amyloid PET is
not useful for staging the severity of a dementia
syndrome [85].
Acquisition and analyzing techniques
Imaging with 11C-PiB can be performed either by
a dynamic PET acquisition beginning immediately
upon tracer injection (typically of 90 min duration), or
late static imaging of 20–30 min duration preceded by
a tracer uptake period (40 or 50 min) [86] to produce
an image that approximates the steady state distribu-
tion of tracer concentration in tissue relative to that
in plasma. Dynamic imaging is, however, impractical
for routine clinical practice. Comparison with kinetic
analysis of dynamic 11C-PiB PET, it has been demon-
strated that reliable and reproducible quantification
of 11C-PiB binding can be obtained via simplified
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analysis of static imaging using SUVr, with the cere-
bellar cortex acting as the reference region [59, 87].
In a clinical setting, static imaging with 18F-
florbetapir, 18F-flutemetamol, and 18F-florbetaben
can be performed approximately 60, 90, and 130 min,
respectively, after tracer administration [72, 88–90].
As for 11C-PiB, reliable A quantification can be
achieved for these 18F-labelled amyloid tracers with
20 min imaging and SUVr analysis relative to the
cerebellar cortex. In a recently published meta-
analysis of studies with 18F-labelled A tracers in
AD, results indicated favorable specificity and sen-
sitivity in the differentiation of AD patients from
age-matched normal controls. Both 18F-florbetapir
and 18F-florbetaben demonstrated sensitivity and
specificity of over 87%, and though there were
insufficient data for complete analysis for 18F-
flutemetamol, results from a phase II trial indicated
greater than 92% sensitivity and specificity in differ-
entiating AD from cognitively normal subjects [71,
91]. Comparisons between 11C-PiB and 18F-labeled
amyloid ligands have also yielded high correlations
for SUVr quantification of static imaging in cortical
areas, although 11C-PiB is superior in differentiat-
ing between controls and AD patients [80–82]. More
recently, a common scale—namely Centiloid—for
quantifying A PET data has been developed, so
as to allow standardization of results across differ-
ing A radiotracers and imaging protocols [92]. It
scales the outcome of each analysis method to a 0 to
100 scale anchored by young controls (≤45 years)
and typical AD patients. A single cut point of 1.42
SUVr (Centiloid 19) has also been defined for amy-
loid PET based on the reliable worsening cut point
methods [49]
Clinical implementation
While amyloid PET is considered the most sen-
sitive and specific biomarker for AD, its utility in
clinical setting is under vigorous evaluation. The
most important role of clinical amyloid PET at this
stage is to confirm the diagnosis of AD when the
clinical presentation is atypical or to differentiate
between amyloid associated dementia with non amy-
loid pathology. With the current therapeutic options,
there is no clinical indication to perform amyloid
imaging in straightforward advanced AD cases with
high clinical probability as the result is most likely
positive. Amyloid imaging also cannot differentiate
between clinical variants of AD (typical amnestic
AD versus posterior cortical atrophy versus logopenic
variant of PPA) or AD from other amyloid associated
dementia (DLB or dementia with cerebral amyloid
angiopathy). The role of amyloid PET for diagnosis
of AD is summarized in Fig. 5. It is worth empha-
sizing that should AD specific disease modifying
therapies become available in the future, the rec-
ommendation should change accordingly. This will
expand the current application of amyloid PET in
clinical settings.
Since deposition of amyloid plaques in brain is one
of the first pathological changes in the course of AD
[50], amyloid PET can detect brain abnormality at
very early stages of the disease or in MCI/preclinical
AD cases when the clinical diagnosis is less cer-
tain but the intervention will be more effective. The
main caveat in using amyloid imaging in preclinical
AD is that 10–30% of cognitively normal individu-
als can have positive amyloid PET [66, 93, 94]. The
long-term prognosis in this group and the time scale
that they may develop cognitive decline are not com-
pletely clear. Therefore, the result of amyloid imaging
should be interpreted by dementia experts and based
on the cognitive status and clinical presentation of the
case. It is very important to remember positive amy-
loid PET alone does not confirm the diagnosis of AD
or MCI.
The disclosure of the results to a patient and care-
giver is another sensitive issue that needs special
attention. It might be stressful news for patients
and can pose legal and social constraints on their
life. The Canadian consensus on the use of amy-
loid imaging [85] has recommended adopting the
disclosure methods developed by Harkins et al. [95].
It includes educational session about the results of
amyloid imaging and their meaning, assessment of
mood and willingness of the participant to receive the
results and then face-to-face disclosure session pro-
viding written report and explaining the implications
with time for questions.
Single photon emission computed tomography
Perfusion hexamethylpropyleneamine oxime
(HMPAO)-SPECT measures cerebral blood flow
(CBF). It shows hypoperfusion in the regions that
demonstrate low glucose metabolism on 18F-FDG-
PET such as temporoparietal cortex and posterior
cingulate gyrus. A number of guidelines [3, 6, 8]
advocate SPECT as an alternative to 18F-FDG-PET
but it has been shown that FDG has higher sensi-
tivity and specificity for the diagnosis of AD and
DLB [96]. In day-to-day practice, the utility of
HMPAO-SPECT (CBF-SPECT) is dependent on
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Fig. 5. Stepwise algorithm of PET imaging in the evaluation of AD. Patients who fulfill the criteria for PET imaging, can be imaged by
FDG-PET or SPECT. If FDG-PET is inconclusive, amyloid imaging will be the next step. The dashed lines are demonstrating the role of
tau PET when it becomes clinically available.
the availability of SPECT or 18F-FDG-PET in each
center. Currently the UK National Institute of Health
and Care Excellence recommend HMPAO-SPECT
to differentiated AD from vascular dementia and
FTD prior to FDG [3]. While the Fourth Canadian
Consensus Conference on Diagnosis and Treatment
of Dementia [6] suggested using SPECT as an
alternative to FDG when PET cannot be performed.
Dopaminergic iodine-123-radiolabelled 2 -carbo
methoxy-3 -(4- iodophenyl)-N-(3-fluoropropyl)
nortropane (FP-CIT) SPECT known commercially
as DaTSCANTM (GE Healthcare, Waukesha, WI,
USA) depicts striatal uptake of dopamine. Low
dopamine transporter uptake in basal ganglia is a
characteristic feature of DLB. Dopaminergic SPECT
has very high sensitivity and specificity for diagnos-
ing DLB [97], however it cannot distinguish DLB
from other nigrostriatal neurodegenerative disorders
associated with presynaptic dopaminergic deficiency
such as PDD, PSP, CBD, or FTD with Parkinsonism.
Both The UK National Institute of Health and Care
Excellence [3] and The European Federation of
the Neurological Societies [8] recommend using
dopaminergic SPECT in diagnosis of cases with
suspected dementia with Lewy bodies.
Other imaging techniques
Tau-PET
Despite the high sensitivity of amyloid imaging
in diagnosis of AD, there is a 15–20 year time lag
between A deposition and clinical symptoms in AD.
By the time patients become symptomatic, the amy-
loid load has reached its plateau phase which means
amyloid PET cannot be used as a staging or prog-
nostic biomarker. On the other hand, the presence
of neurofibrillary tangles, phosphorylated tau pro-
tein aggregates, in AD has close association with
cognitive decline [98], severity of dementia symp-
toms [99], neuronal injury [100], and brain atrophy
[101]. Therefore, tau imaging can be used as a surro-
gate marker to predict cognitive decline or disease
progression in AD. Tau aggregation and deposi-
tion in AD occurs in a stereotypical spatiotemporal
N. Sheikh-Bahaei et al. / Practical Guide for Imaging Alzheimer’s Disease 81
pattern starting from transentorhinal/entorhinal cor-
tex to hippocampus and then extending to the rest
of temporal lobe and neocortical regions [102].
Widespread neocortical deposition is not common
in cognitively normal individuals and this stepwise
pattern of deposition can help to stage AD. The poten-
tial role of tau PET is depicted in Fig. 5. When
patient is amyloid positive (A+) but doesn’t have
any evidence of neurodegeneration on FDG-PET or
structural MRI (N–), presence of tau will increase
the likelihood of AD or determine more advanced
stages of the disease. On the other hand, if a patient is
A + and N + without any evidence of tau, one should
consider neurodegeneration as a consequence of non
AD pathology and possibility of a mixed dementia
syndrome.
Tau imaging might also be useful to facilitate
the diagnosis of non-amyloid dependent tau related
dementias including PSP, CBD, PPA, behavioral
FTD, and a group of other pathologies defined as sus-
pected non Alzheimer’s disease pathologies (SNAP).
Examples of SNAP conditions include argyrophilic
grain disease and primary age-related tauopathy
[103]. The distribution pattern of tau aggregates in
different tauopathies is variable: widespread fronto-
temporal distribution in FTD, subthalamic nucleus
and basal ganglia in PSP, neocortical areas and stria-
tum in CBD, dentate gyrus and hippocampus in Pick’s
disease, amygdala and entorhinal cortex and hip-
pocampus in argyrophilic grain disease, and mesial
temporal lobe in primary age-related tauopathy [104].
In recent years, different tau selective PET tracers
have been developed and been used for human stud-
ies: [18F]THK523, [18F]THK5117, [18F]THK5105
[18F]THK5351, [18F]AV1451(T807), and [11C]
PBB3 [105]. Although the initial results are promis-
ing, there is still long way before tau PET could be
qualify for clinical use. If AD specific disease modi-
fying therapies become available, then the indications
of performing tau imaging may also change. Tau PET
can be used as a follow up imaging tool to assess the
response to treatment and predicting future clinical
progression.
MR spectroscopy
MRS is a non-invasive method for measur-
ing the concentration of certain chemicals in the
brain. N-acetylaspartate (NAA), myoinositol (mI),
Choline (Chol), Glutamate plus Glutamine (Glx),
and Creatine (Cr) are the most commonly mea-
sured compounds. A number of studies in the past
two decades have investigated the role of MRS in
neurodegenerative disorders. The rationale is that
brain metabolites act as surrogate markers for dif-
ferent pathological processes such as neural damage,
glial proliferation, loss of membrane integrity, and
even inflammatory changes. MRS has the potential to
be used as an imaging biomarker detecting the early
metabolic changes in AD [106].
Since there is no significant change in the level
of Cr in different conditions, it is commonly used as
an internal reference to overcome any biases. There-
fore, the result of MRS is usually reported as a ratio
of other metabolites over Cr [107, 108]. Decrease in
NAA or NAA/Cr, a marker of neuroaxonal density
and viability, is one of the main reported findings in
AD [109, 110]. Reduction of NAA has been reported
in the medial temporal lobe [111], hippocampi [110],
and posterior cingulate gyrus [112].
In addition to NAA reduction, increase in mI in
several brain regions is considered another feature
of AD [107, 109]. mI is a glial marker and increase
in the level of mI can be a sign of increased glial
content, size, and activation [108]. Increase in mI
or mI/Cr is considered an early event in the course
of AD pathology that can precede NAA reduction
[109]. It has been shown that detection of NAA reduc-
tion and mI increase in suspected AD improves the
specificity and accuracy of the clinical diagnosis sig-
nificantly (100% for distinguishing AD from healthy
controls) [113]. Based on the observed correlation
between the metabolites’ level and histopathological
changes in AD, it has been suggested that reduction in
NAA is related to early tau-mediated dynamic pro-
cesses while increase in mI is associated with A
deposition [114].
Unlike NAA and mI, other metabolites includ-
ing Chol [109, 113, 115] and Glx [112, 116] have
shown inconsistent changes in AD. Lack of standard-
ized techniques and choosing different brain regions
as region of interest might be responsible for these
contradictory results.
In comparison to other functional imaging tech-
niques, MRS is more available and much less
expensive with no radiation risk. It can be easily
added to the structural MRI sequences and extract
very useful functional information to help diagnosis.
Moreover with the correlation between the metabo-
lites level and pathological changes in AD, MRS can
be utilized as a follow up imaging tool in therapeutic
trials. However, to use MRS for clinical purpose, fur-
ther large cohort research is required to standardize
the techniques and compare the results of MRS with
other functional biomarkers.
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Functional MRI and diffuse tensor imaging
Neurodegenerative diseases are associated with
synaptic dysfunction, axonal, and white matter tract
loss with connectivity disruption, and brain network
alteration. Advanced MRI techniques like fMRI and
DTI can provide further information about these
microstructure properties of the brain, its connectivity
and networks.
fMRI can be performed as either rest-state (RS)-
or task-based. RS-fMRI focuses on spontaneous low
frequency fluctuations in blood-oxygen-level depen-
dent signal. Around 10–20 RS networks have been
described and the most common ones are default
mode network (DMN), the salience network, and cen-
tral executive network [117]. Different studies have
shown that there are functional alteration in all these
three networks, particularly DMN in AD and MCI
when compared to healthy controls [118]. Also in
a meta-analysis of task-based fMRI, MCI and AD
patients presented different patterns of hypo-activity;
frontoparietal and DMN were affected in MCI and
visual network demonstrated low activity in AD cases
relative to controls. This implies that pattern of neu-
ronal network dysfunction might be a consequence
of disease progression [119].
DTI measures the directionality of water diffusion.
In the white matter tracts, water diffusion follows the
orientation of the axonal bundles [120]. DTI studies
in AD have shown white matter fiber alteration in
temporal and frontal lobes and also corpus callosum
and posterior cingulate gyrus [121] with a posterior
to anterior gradient [122]. A meta-analysis showed
DTI measurements of limbic regions have modest
diagnostic power in discriminating AD from controls
which was not significantly different to hippocampal
atrophy [123].
These functional alterations appear prior to struc-
tural changes in MRI and could be used as an indicator
of disease progression and to monitor response to
disease modifying drugs. The caveat is that these
techniques are at early stages of evaluation and
require further large cohort studies. Moreover, there is
significant variability of DTI-based diffusion metrics
between MRI scanners that imposes a major restric-
tion in multicenter studies [124]. These limitations
mean there is no prospect of using these methods in
clinical setting in the near future.
Arterial spin labeling
ASL is a non-invasive MRI technique for mea-
suring tissue perfusion (CBF) by using magnetically
labeled arterial blood water protons as an endogenous
tracer [125]. It is known that hypoperfusion of AD
vulnerable regions starts well before clinical symp-
toms. There is high correlation between reduction in
perfusion and glucose metabolism in 18F-FDG-PET.
Some take this further and suggest that vascular dys-
function might precede other abnormalities in AD
and present even prior to A aggregation [126].
Recently, several studies have investigated the
correlation between ASL and FDG-PET/SPECT in
AD. These have shown good concordance between
hypoperfusion in ASL and other established tech-
niques with comparable diagnostic accuracy [127].
The results in MCI cases however, were more contra-
dictory as both hyper- and hypoperfusion have been
reported [126].
Although ASL, with no radiation risk, lower cost
and wider availability, can potentially be a valuable
technique to measure brain perfusion, it still has
some limitations for wide clinical application: ASL
is sensitive to blood velocity and arterial transit
time; images are dependent on the integrity of the
cerebrovascular system and therefore, presence of
steno-occlusive disease or other cerebrovascular
pathology can interfere with the quality of image
and lead to artefact or noise; it is also highly affected
by head motion [127]. New methods have been
developed to overcome some of these limitations but
further research studies are required before ASL can
be considered as a diagnostic biomarker for AD in
clinical setting.
CONCLUSION
1) Imaging biomarkers are an essential part of
workup in CDS. Appropriate and informed
application of imaging can help clinicians in
making early diagnosis or dealing with atypical
cases of dementia.
2) Structural imaging (MRI or high resolution CT)
should be the first tier of imaging in CDS. Using
dementia specific protocol is very crucial for
both diagnosis and follow up. Hippocampal and
MTL atrophy can be evaluated visually or using
quantitative techniques. Visual dichotomized
assessment (atrophic vs not atrophic) has good
reliability.
3) Functional imaging can provide further infor-
mation about the pathophysiology of the AD but
their utility in day-to-day practice is still under
investigation. Currently, they are recommended
when clinical examination and structural imag-
ing cannot confirm the diagnosis.
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4) Hypometabolism in 18F-FDG-PET, an indi-
cator of neurodegeneration, can differentiate
dementia from normal aging. Absence of sig-
nificant hypometabolism however, will not
exclude AD pathology completely particularly
at an early stage.
5) Although 18F-FDG-PET is more available com-
pared to amyloid PET, interpretation of 18F-
FDG PET can be more challenging. Standard-
ized cut point and development of new analysis
software might help wider group of dementia
experts to use FDG in their routine practice.
6) Amyloid imaging will be more accessible
in the near future with the new fluorinated
amyloid tracers. Therefore, it is crucial for
clinicians to know the indications of amyloid
PET in the clinical setting. The result of PET
imaging should always be interpreted by
dementia experts and within the context of the
clinical examination. Positive amyloid PET
(A+) alone is not equal to AD while A- makes
AD pathology very unlikely.
7) Other functional imaging techniques have
shown promising results but are still far from
being used in the clinical setting.
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